BioPharmaceutical Business Intelligence

  • Uncover prior art in expired and abandoned patents
  • Obtain formulation and manufacturing information
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Cerilliant
Mallinckrodt
Dow
Farmers Insurance
Fuji
Merck
Teva
Daiichi Sankyo
Johnson and Johnson

Generated: January 19, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,432,452

« Back to Dashboard

Which drugs does patent 6,432,452 protect, and when does it expire?

Patent 6,432,452 protects PICATO and is included in one NDA.

This patent has eighteen patent family members in fifteen countries.
Summary for Patent: 6,432,452
Title: Anti-cancer compounds
Abstract:This invention relates to a compound or group of compounds present in an active principle derived from plants of the species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
Inventor(s): Aylward; James Harrison (St. Lucia, AU)
Assignee: Peplin Biotech Pty. Ltd. (Fortitude Valley, AU)
Application Number:09/486,199
Patent Claim Types:
see list of patent claims
Use; Process;

Drugs Protected by US Patent 6,432,452

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-001 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF ACTINIC KERATOSIS ➤ Subscribe
Leo Labs PICATO ingenol mebutate GEL;TOPICAL 202833-002 Jan 23, 2012 RX Yes Yes ➤ Subscribe ➤ Subscribe TREATMENT OF ACTINIC KERATOSIS ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,432,452

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
AustraliaPO 8640Aug 19, 1997
PCT Information
PCT FiledAugust 19, 1998PCT Application Number:PCT/AU98/00656
PCT Publication Date:February 25, 1999PCT Publication Number: WO99/08994

Non-Orange Book US Patents Family Members for Patent 6,432,452

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,787,161 Anti-cancer compounds ➤ Subscribe
6,844,013 Methods of stimulating the immune system ➤ Subscribe
7,410,656 Anti-cancer compounds ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 6,432,452

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 397580 ➤ Subscribe
Australia 736230 ➤ Subscribe
Australia 8721798 ➤ Subscribe
Australia PO864097 ➤ Subscribe
Brazil 9811327 ➤ Subscribe
Canada 2301082 ➤ Subscribe
China 1266421 ➤ Subscribe
Cyprus 1108303 ➤ Subscribe
Germany 69839586 ➤ Subscribe
Denmark 1015413 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
Covington
QuintilesIMS
Novartis
McKesson
Accenture
Cerilliant
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot